July 2009

In this Issue: Features | Partner Spotlight | Calendar | Welcome New Partners | In the News | Interesting Information | Contact Us

New Medicines in Development

All patients, whether fighting a deadly disease or managing a chronic condition, live in hope of new medicines and improved therapies. America's research-based biopharmaceutical companies are meeting these hopes with new medicines and treatments that improve health and give patients and physicians better treatment options.

America's research-based biopharmaceutical companies are committed to continuing and expanding innovative research and developing new and better medicines and treatments. Each year, dozens of new medicines and therapies are added to the medical arsenal in the fight against disease. These new medicines are part of the steady-stream of medical and therapeutic advances that are revolutionizing and improving healthcare. They are the result of medical research and development that can take as long as 15 years and cost more than $1.3 billion dollars to bring a new medicine from the laboratory to a pharmacy shelf.

Click here to learn more about new medications being developed to treat specific diseases and different populations.

Molina Healthcare

Mission
Molina Healthcare is committed to being a national leader in providing quality, affordable healthcare to families and individuals who depend on government assistance.

About
Since 1980 Molina Healthcare has been a leader in providing quality healthcare to those who depend on government assistance. Our commitment to our members has made us a national leader in providing affordable healthcare to families and individuals. During this time, we've become one of the most experienced managed healthcare companies in the country. We work with Medicaid and Medicare, among other government programs. Currently we provide healthcare assistance to over a million members in nine states.

Web site
www.molinahealthcare.com

CPAT Seminars:

July 30, 2009
CPAT Webinar "Reforming America's Healthcare System: A Comprehensive Overview of the Ongoing Debate and Implications"

Featuring Guest Speaker: Dr. Benjamin E. Sasse
U.S. Assistant Secretary of Health and Human Services, 2007-2009

In Northern California, please contact Charlotte at (916) 658-0144 or charlotte@perrycom.com

In Southern California, please contact Brandon at (323) 466-3445 or brandon@cerrell.com

Check out our CPAT partner events occurring this month!

• Aegis of San Francisco
• AframGlobal Organization Inc/Village Projects
• Be Transformed, Inc. - Faith Based-Drug & Alcohol Treatment Service
• Derek Silva Community - Catholic Charities CYO
• Harold Joon Pyun Consulting
• Mammography Screening of Alameda
• Molina Healthcare Inc.
• National Multiple Sclerosis Society - Southern California Chapter
• National Spasmodic Torticollis Association
• Northeast Valley Health Corporation - Health Education Department
• Pacific Hospital of Long Beach
• Padres Unidos de South Gate
• Waking in Community...A Project of Community Partners
• Wellness Community, The - Redondo Beach
• 3 individual partners

CPAT in the News!

African American Health Forum Comes to Riverside
Black Voice News, June 24, 2009
Taking care of your body and staying healthy is a vital role in life. On Wednesday, June 17 at the Marriott in Riverside California Partnership Access to Treatment held an informative luncheon entitled, "Depression in African Americans."

CPAT Partner in the News!

Latina Breast Cancer Agency
The Today Show, June 16, 2009

Would you like to share a recent article featuring your organization? Contact Charlotte Phillips at charlotte@perrycom.com to include the story in our next edition of CA Access News.

Innovation called vital for biotech to survive
San Francisco Chronicle, June 26, 2009
Biotech firms need a new burst of innovation in fields like diagnostic testing and biofuels production to adapt to a changing marketplace. Five of the world's top-10 selling medicinal compounds were developed by biotech firms, a remarkable achievement considering they compete against much larger pharmaceutical companies.

New Drugs May Ease Side Effects Of Chemo
KCBS-TV, June 25, 2009
Researchers in Britain say they may have found the "Holy Grail" of cancer research. PARP inhibitors are part of a new wave of cancer research, called "targeted chemotherapy." What makes them different from traditional chemotherapy drugs is that they are able to target and kill cancer cell and leave healthy cells alone.

Sunnyvale pharmaceutical company gains worldwide reach
San Jose Business Journal, June 12, 2009
Pharmacyclics Inc. is making inroads into the global marketplace. The clinical-stage biopharmaceutical company develops small-molecule drugs for cancer treatment, and it has partnered with a French pharmaceutical company to develop and distribute one of its drugs outside the United States.

Top Democrat pushes for action on biotech drugs
San Francisco Chronicle, June 8, 2009
As the Obama administration renews its health care reform effort on Capitol Hill, a top Democrat is calling for speedy action on a yearslong effort to create generic competition for costly biotech drugs.

Glaxo and Pfizer create new HIV drug company
San Jose Mercury News, April 16, 2009
Pharmaceutical giants GlaxoSmithKline and Pfizer will pool their resources to create a new company to develop and sell HIV medicines, leveraging a minimal investment into a market-leading position.

Below is a list of common diseases with new medicines currently in development:

Cancer:
Pharmaceutical researchers are now working on 861 medicines for cancer. All are in either clinical trials or under Food and Drug Administration review. The medicines in development for cancer include: 122 for lung cancer, 106 for breast cancer, 103 for prostate cancer, and 70 for colorectal cancer.

Heart Disease and Stroke:
There are currently 312 medicines in development for two of the three leading causes of death in Americans -- heart disease and stroke. All of the medicines are either in clinical trials or awaiting approval by the Food and Drug Administration. The medicines in development for heart disease and stroke include 36 for high blood pressure, 33 for heart failure, 16 for heart attacks, and 22 for stroke.

HIV/AIDS:
HIV/AIDS is one of the world's most devastating diseases. To help fight it, pharmaceutical and biotechnology researchers are testing 109 medicines for HIV/AIDS and related conditions and intensifying their work towards the development of vaccines.

Mental Illness:
Pharmaceutical research is targeting mental illnesses with 197 medicines in development to help more than 450 million people worldwide who suffer from some form of mental illness -- from Alzheimer's disease to depression to schizophrenia to dependence on alcohol or illegal drugs. All of the medicines are either in clinical trials or awaiting approval by the Food and Drug Administration.

Neurological Disease:
Studies show that older patients are particularly susceptible to many neurologic diseases including Alzheimer's, epilepsy, Parkinson's, and stroke. In addition to the terrible human toll of neurologic disorders, the diseases annually cost the U.S. economy hundreds of billions of dollars in care, lost work-days, and reduced productivity -- Alzheimer's disease alone costs more than $148 billion a year, according to The Alzheimer Association.

925 L Street, Suite 1200
Sacramento, CA 95814
www.caaccess.org

Supported by America's Pharmaceutical Research Companies

If you do not wish to receive future issues of CA Access News, please send an e-mail to info@caaccess.org requesting to be deleted from the mailing list. Please be sure to include the e-mail address where you are receiving newsletters.